The Study
Rheumatoid arthritis (RA) is a prototype immunemediated infl ammatory disease, characterised by a symmetric polyarthritis usually involving the small joints of the hands and feet. Other joints can also be involved. Rheumatoid factor (RF) and/or anticitrullinated protein antibody (ACPA) positive ('seropositive') RA is associated with more aggressive articular disease, a higher frequency of extraarticular manifestations and increased mortality. 1 RA is still associated with signifi cant morbidity despite major developments in antirheumatic therapy. Among the infl ammatory joint diseases, RA is the commonest and the most important in socioeconomic terms.
Over the past few years, research in the fi eld of RA has focused on the earliest stages of disease, leading to the discovery that circulating autoantibodies, specifi cally immunoglobulin M-RF and ACPA, and increased acute phase reactants precede the clinical onset of the disease. [2] [3] [4] [5] These autoantibodies are present a median of 5 years before clinical symptoms appear. 3 Subjects with arthralgia and these autoantibodies have an approximately 30% chance of developing RA within 1 year. 6 These data form strong evidence that clinical signs and symptoms may be preceded by a preclinical phase for several years, and that the preclinical and earliest clinically apparent phases of RA are likely to represent important therapeutic windows within which clinical outcomes can be dramatically modulated. 7 Factors such as smoking, which act during the preclinical phase, leading to citrullination of peptides and ACPA formation, 8 are increasingly being recognised.
To facilitate research in this area, the European League Against Rheumatism (EULAR) Standing Committee on Investigative Rheumatology established a study group in February 2011 to build a European network of excellence. Key aims of this study group were to develop a more accurate understanding of the mechanisms driving the immunological abnormalities seen during the preclinical phase of RA and the stimuli that turn such abnormalities into a joint-centric disease, in order to inform clinically relevant developments in outcome prediction and therapy.
The initial remit of the study group was to agree on terminologies to be used during the preclinical and earliest clinically apparent phases of RA and to defi ne important research questions. This report describes this process and its conclusions.
METHODS AND RESULTS

Terminology for describing phases of RA
To facilitate discussion about terminologies to be used in the phases of disease before individuals develop RA, a three-stage structured process was followed.
Stage 1
Brief summaries of widely accepted phases that individuals (may) pass through before the development of RA (box 1) were circulated to participants (19 key researchers in the fi eld; rheumatologists, basic scientists and a patient representative), who were asked to provide descriptive terms for these phases, and to comment on their chosen descriptive terms. Participants were asked to identify whether they felt that there were other phases that should be considered in the context of the development of descriptive terms. Terms that are currently widely used to describe individuals in phases before the development of RA (box 2) were circulated to participants who were asked to state whether they felt the terms were useful and to comment further on them. Fifteen responses were received for stage 1.
Stage 2
Anonymised data from stage 1 were fed back to participants before a 2-day meeting.
Stage 3
Eighteen of the participants met during a 2-day workshop. Anonymised responses from previous stages were presented and discussed at the meeting. The following key issues were discussed. First, there was extensive discussion about the terms 'pre-RA' and 'preclinical RA'. It was felt that it was only appropriate to use these in situations in which one knew that the fi nal outcome was RA and when one was looking backwards through the patient's history describing particular phases the patient had gone through. In particular, there was consensus that the term 'pre-RA' suggested that the patient would defi nitely progress to RA; without a set of risk factors that were 100% specifi c it was felt that the term was inappropriate and, as highlighted by the patient representative, of concern to patients and their families if it was used as a shorthand for those individuals identifi ed at high risk of RA.
Second, there was consensus that the terminology used should be able to refl ect that the different phases: do not occur in all patients who eventually develop RA (eg, some patients may never have evidence of autoantibodies associated with RA during the preclinical phase of disease); do not necessarily occur in the same order in all patients (eg, some patients may develop autoantibodies before the development of infl ammatory joint symptoms and other patients may develop these after the development of such symptoms).
Following these discussions a draft proposal for terminology was developed and this was further refi ned. The fi nal consensus is shown in box 3.
Recommendations for reporting of the phases of clinically apparent disease
Currently there is a diversity of approaches to the dating of 'onset' in cohorts of patients with RA including from: the onset of any joint symptoms related to the current episode including arthralgia/morning stiffness; the onset of self-reported joint swelling; the onset of clinically observed swelling; the time of fulfi lment of classifi cation criteria for RA.
During the 2-day meeting, a consensus was reached that, as best practice, in prospective cohort studies the following dates are recorded: (1) First musculoskeletal symptoms relevant (in the opinion of the assessing rheumatologist) to the current complaint. EULAR) based on the rheumatologist's assessment. It was recognised that it may not be feasible in all situations to collect all these data. However, it was felt that in all situations investigators should report clearly what they were using as their 'starting point' when reporting symptom/disease durations.
Future research agenda
During the 2-day meeting a number of areas were identifi ed as being in need of urgent investigation:
Identifi cation of additional risk factors and biomarkers and analysis of interactions between these as individuals progress through different phases of disease
The need to identify additional risk factors and biomarkers for the development of RA was unanimously agreed. Each established and putative factor will have to be clearly defi ned, in order to harmonise the classifi cation of individuals between cohorts, for example as a precise genotype rather than an allelic odd ratio for a genetic factor. A clear need was identifi ed for an assessment of which phases these were risk factors/ biomarkers for. For example, a particular risk factor may be relevant only to progression to the development of systemic autoimmunity associated with RA, but if assessed in patients in that phase would not be a risk factor for progression though to the development of RA. In contrast, a different risk factor may be relevant to progression from unclassifi ed arthritis to the development of RA. Using the knowledge of risk factors important in each phase, risk stratifi cation and prediction models might identify those individuals who would benefi t from intervention applicable to that phase.
Prediction of clinically relevant outcomes in addition to the development of RA
The heterogeneous nature of RA was acknowledged and it was agreed that, in addition to predicting the development of RA, research should look at biomarkers and risk factors for the rate of progression of joint destruction and the development of extra-articular manifestations of RA (eg, cardiovascular disease and pulmonary fi brosis) that could be identifi ed in individuals 'at risk' of RA. Factors related to remission would also be of interest. The possible infl uence of the timing and intensity of therapy on these longer-term outcomes should be acknowledged.
Systemic autoimmune phase and site(s) of disease initiation
The term 'systemic autoimmunity associated with RA' was felt to be the best to describe the phase during which abnormalities in various body compartments can be found preceding the clinical expression of the disease. Although the synovium is the principal site of pathology in the established phase of disease, it may not be the site where the disease is initiated. Systemic immune abnormalities in individuals without joint symptoms, and a lack of immune infi ltrates in the synovium during the earliest phase before clinical signs and symptoms of arthritis, 7 point to other tissues being important in the initiation of adaptive immune reactions. Important tissues for research include bone marrow, lymph nodes, the gut, periodontal tissue, 11 the lung 8 and the neuroendocrine system. An initial phase, characterised by systemic autoimmunity without synovial infl ammation, may be followed by a shorter phase during which asymptomatic synovitis is present. 12 13 Based on the results of research on various tissues during different stages of the disease, it may be possible to develop specifi c preventive interventions targeting the breaking of tolerance or the formation of autoantibodies.
Symptoms without clinical arthritis phase
It was widely recognised that many patients with RA have a period of symptoms likely to be related to the development of infl ammatory joint disease before they develop clinical arthritis. Two important areas for research were identifi ed within this phase. First, the signifi cance of synovial and bone abnormalities as assessed by imaging (eg, ultrasound or MRI), which may detect changes such as synovial thickening, increased synovial vascularity and bone marrow oedema in patients with symptoms without clinical arthritis, as predictors of progression to unclassifi ed arthritis and the development of RA. Second, the importance of identifying symptoms/complexes of symptoms that are associated with the subsequent development of RA.
DISCUSSION
The characterisation of genetic and environmental risk factors for RA, and the identifi cation of blood-based biomarkers predictive of development of RA in as yet asymptomatic individuals, has led to increasing interest in the development of predictive and preventive strategies that can be used before the onset of symptoms. This comes against a background of considerable research looking at predictive and therapeutic approaches in patients with symptoms before they fulfi l the classifi cation criteria for RA. 6 14-19 These criteria 9 10 have allowed for a common understanding of what we mean by this phase in the patient's journey. There is, however, a plethora of terms currently used to describe individuals in disease phases before the fulfi lment of classifi cation criteria for RA, including 'early RA', 'very early RA' and 'pre-RA'. The recommendations in this paper propose guidance on approaches to describe specifi c phases before the development of RA, which are infl uenced by our current thinking about aetiopathogenesis. The use of these terms in the manner suggested will facilitate communication between researchers and comparisons between studies, in much the same way that classifi cation criteria facilitate recruitment of patients with similar clinical phenotypes to clinical trials. An important outcome from the meeting was a decision to recommend that the use of the term 'pre-RA' should be limited to very specifi c situations. The prefi x 'pre-RA with:' can be used before any/any combination of (a) to (e) but only to describe retrospectively a phase an individual was in once it is known that they have developed RA.
The terms used to describe the different phases before the development of RA are intentionally broad. Therefore, 'genetic risk factors for RA' and 'environmental risk factors for RA' deliberately do not defi ne any particular genetic and environmental risk factors. 'Systemic autoimmunity associated with RA' does not defi ne any specifi c immune abnormalities, such as any specifi c autoantibody, and 'symptoms without clinical arthritis' does not defi ne any specifi c symptoms. This was a very conscious decision, as restricting these categories by specifying risk factors and features that are currently known will render the nomenclature rapidly redundant in this advancing fi eld. Future research will defi ne additional risk factors and features relevant to each of these phases, beyond current knowledge, and will assess the predictive utility of each of these. In addition, there are currently recognised biomarkers that are known to be present before the development of RA, which are not specifi cally refl ected in the nomenclature. The presence of synovitis on imaging, but not clinically, is an example of this. This is not to suggest that the study group viewed this as an unimportant biomarker. Rather, the nomenclature should provide a framework within which future research can assess at which phases, and for transit to which phases, this, like other biomarkers, is useful.
A number of the research questions that have been defi ned require new cohorts, of asymptomatic individuals and of patients, to be established and new techniques to be developed to image and collect material from different sites. The identifi cation of uniform core datasets that can be collected in standardised ways across cohorts is an important goal. Furthermore, standard operating procedures for the collection, handling and storage of samples, such as serum and RNA, should be agreed to ensure good and consistent quality of the biomaterial. Given the inherent confl ict between the desire to collect material in a uniform and optimal manner and the constraints of working in a clinical environment where such collection is not always feasible, the description of how each sample was collected, handled and stored, will be very important.
As knowledge evolves it is important not to leave its true target audience behind. Individuals without RA need to be informed of the rationale for and value of predicting risk and intervening and the need to have a clear understanding of the risks and benefi ts of such approaches. Clarity of terminology and the involvement of users through all phases of the research process will help achieve this.
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